表紙
市場調查報告書

關注市場分析:肥胖

Market Spotlight: Obesity

出版商 Datamonitor Healthcare 商品編碼 917495
出版日期 內容資訊 英文 62 Pages
商品交期: 最快1-2個工作天內
價格
關注市場分析:肥胖 Market Spotlight: Obesity
出版日期: 2020年02月11日內容資訊: 英文 62 Pages
簡介

本報告提供肥胖治療市場相關分析,疾病概要和患者數的變化、預測,目前的主要治療方法,法規環境和近幾年主要的事件,現在開發中臨床實驗的進展上市計劃,主要的治療藥的市場趨勢預測,資本交易的動向等調查。

概要

要點

疾病的背景情況

治療方法

  • 醫藥品
  • 手術

流行病學

已上市醫藥品

開發平台藥物

最新活動、分析師的見解

不久將來的活動

法規相關的主要的活動

成功的可能性

授權合約、資產收購交易

母體專利

商機

臨床實驗形勢

  • 贊助商數:各狀態
  • 贊助商數:各階段 (相位)
  • 近幾年趨勢

相關分析

  • 處方藥的資訊

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0199735

This Market Spotlight report covers the Obesity market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

Datamonitor Healthcare estimates that in 2017, there were approximately 681.3 million prevalent cases of obesity in adults (aged 20+ years) worldwide, and expects that number to increase to 762.9 million prevalent cases by 2026.

In the same year, Datamonitor Healthcare estimates that there were 126.6 million prevalent cases of obesity in children and adolescents (aged 5-19 years) worldwide, and expects that number to increase to 134.0 million prevalent cases by 2026.

Prevalence proportions are highest in Northern America and lowest in Asia. The approved drugs in the obesity space target gastric lipase, dopamine, norepinephrine (noradrenaline), dopamine reuptake, norepinephrine (noradrenaline) reuptake/transporter, opioid receptors, GABA-A receptor, serotonin 5-HT2C receptor, and glucagon-like peptide-1 (GLP-1) receptor. The majority of marketed drugs are administered via the oral route, with one product being available in a subcutaneous formulation.

The majority of industry-sponsored drugs in active clinical development for obesity are in Phase I, with two drugs in Phase III. Therapies in development for obesity focus on a wide variety of targets, with the subcutaneous route being the most common method of delivery.

High-impact upcoming events for drugs in the obesity space comprise expected PDUFA dates for Qsymia, Belviq, and Belviq XR, topline Phase II trial results for AM833, topline Phase III trial results for Ozempic, and an expected decentralized EU approval as well as an estimated EU patent expiration for Qsymia.

The overall likelihood of approval of a Phase I obesity asset is 2.6%, and the average probability a drug advances from Phase III is 62.5%. Drugs, on average, take 8.5 years from Phase I to approval, compared to 8.9 years in the overall metabolic space.

There have been 34 licensing and asset acquisition deals involving obesity drugs during 2015-20. The largest deal was the $301.1m collaboration and license agreement signed in 2017 between Boehringer Ingelheim and Gubra for the development of novel peptide compounds to treat obesity.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for obesity have been in the early and midphases of development, with 66% of trials in Phase I-II, and 34% in Phase III-IV.

The US has a substantial lead in the number of obesity clinical trials globally. The UK leads the major European markets, while Japan has the top spot in Asia.

Clinical trial activity in the obesity space is dominated by completed trials. AstraZeneca has the highest number of completed clinical trials for obesity, with 76 trials.

Novo Nordisk leads industry sponsors with the highest overall number of clinical trials for obesity, followed by AstraZeneca.

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • Medications
  • Surgery

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • HM12525A for Obesity (July 3, 2019)
  • NS-0200 for Obesity (June 8, 2019)
  • PLENITY for Obesity (April 14, 2019)
  • PLENITY for Obesity (March 25, 2019)
  • Qsymia for Obesity (January 15, 2019)
  • Lap-Band System for Obesity (December 17, 2018)
  • Obalon Balloon System for Obesity (November 15, 2018)
  • TransPyloric Shuttle for Obesity (November 14, 2018)
  • Obalon Balloon System for Obesity (November 13, 2018)
  • PLENITY for Obesity (November 13, 2018)
  • Belviq for Obesity (October 4, 2018)
  • Belviq for Obesity (August 26, 2018)
  • Belviq for Obesity (July 17, 2018)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Preparing For Qsymia Launch In Korea
  • BaroNova's TransPyloric Shuttle Earns FDA Approval To Treat Obesity
  • Gelesis's Plenity Obesity Product Earns De Novo For Wide BMI Range

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Novo/Fauna Partnership Includes Options To Resulting Drug Candidates
  • Novo Nordisk Enters Its First Strategic RNAi Pact
  • Numaferm And Polpharma Sign Deals
  • BI Inks Second Obesity Pact With Denmark's Gubra
  • Merck Extends Research Collaboration With NGM By Two Years

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of obesity in adults, 2017-26
  • Figure 2: Overview of pipeline drugs for obesity in the US
  • Figure 3: Pipeline drugs for obesity, by company
  • Figure 4: Pipeline drugs for obesity, by drug type
  • Figure 5: Pipeline drugs for obesity, by classification
  • Figure 6: NS-0200 for Obesity (June 8, 2019): Phase II - NS-WM-01
  • Figure 7: TransPyloric Shuttle for Obesity (November 14, 2018): ENDObesity II (US)
  • Figure 8: PLENITY for Obesity (November 13, 2018): Phase II - GLOW (EU & US)
  • Figure 9: Belviq for Obesity (October 4, 2018): Phase IV - CAMELLIA-TIMI 61 (CVOT Trial)
  • Figure 10: Belviq for Obesity (August 26, 2018): Phase IV - CAMELLIA-TIMI 61 (CVOT Trial)
  • Figure 11: Belviq for Obesity (July 17, 2018): Phase IV - CAMELLIA-TIMI 61 (CVOT Trial)
  • Figure 12: Key upcoming events in obesity
  • Figure 13: Probability of success in the obesity pipeline
  • Figure 14: Licensing and asset acquisition deals in obesity, 2015-20
  • Figure 15: Parent patents in obesity
  • Figure 16: Clinical trials in obesity
  • Figure 17: Top 10 drugs for clinical trials in obesity
  • Figure 18: Top 10 companies for clinical trials in obesity
  • Figure 19: Trial locations in obesity
  • Figure 20: Obesity trials status
  • Figure 21: Obesity trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of obesity in adults, 2017-26
  • Table 2: Prevalent cases of morbid obesity in adults, 2017-26
  • Table 3: Prevalent cases of obesity in children and adolescents, 2017-26
  • Table 4: Prevalence proportions of obesity and morbid obesity, 2017
  • Table 5: Marketed drugs for obesity
  • Table 6: Pipeline drugs for obesity in the US
  • Table 7: HM12525A for Obesity (July 3, 2019)
  • Table 8: NS-0200 for Obesity (June 8, 2019)
  • Table 9: PLENITY for Obesity (April 14, 2019)
  • Table 10: PLENITY for Obesity (March 25, 2019)
  • Table 11: Qsymia for Obesity (January 15, 2019)
  • Table 12: Lap-Band System for Obesity (December 17, 2018)
  • Table 13: Obalon Balloon System for Obesity (November 15, 2018)
  • Table 14: TransPyloric Shuttle for Obesity (November 14, 2018)
  • Table 15: Obalon Balloon System for Obesity (November 13, 2018)
  • Table 16: PLENITY for Obesity (November 13, 2018)
  • Table 17: Belviq for Obesity (October 4, 2018)
  • Table 18: Belviq for Obesity (August 26, 2018)
  • Table 19: Belviq for Obesity (July 17, 2018)
  • Table 20: Historical global sales, by drug ($m), 2014-18
  • Table 21: Forecasted global sales, by drug ($m), 2020-24